Entopsis pursues 'strategic alternatives' for OpsisDx platform

By LabPulse.com staff writers

October 8, 2021 -- Entopsis has announced that it will pursue strategic alternatives for its OpsisDx urine-based technology platform that offers a diagnostic test for detecting early-stage cancers.

The company said it has engaged with Berkery Noyes as its financial advisor to assist in the endeavor. OpsisDx detects urine chemical signatures through a proprietary array and delivers results via the company's machine-learning algorithms.

Entopsis said validation studies on OpsisDx initially focused on detecting early-stage cancers, and the platform has now expanded to detect multiple other diseases.

Copyright © 2021 LabPulse.com

Last Updated ls 10/8/2021 10:50:26 AM